TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

This trial is testing a new cancer-fighting injection called TAA06 for children and young people with neuroblastoma — a cancer of the nervous system — that has come back or stopped responding to previous treatment. TAA06 is designed to target a protein called B7-H3, which is found on the surface of neuroblastoma cancer cells. **You may be eligible if...** - You are at least 1 year old - You have been diagnosed with relapsed or refractory neuroblastoma (cancer that returned or didn't respond to standard treatment) - Your cancer cells test positive for the B7-H3 protein - You have at least one measurable tumor site - Your heart, liver, and kidney function are within acceptable ranges - Your overall health status (performance score) meets study requirements - You are expected to survive at least 3 months **You may NOT be eligible if...** - You require long-term immune-suppressing medications - Your organ function does not meet the study's minimum requirements Talk to your doctor to see if this trial is right for you.